Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Liquidia CorporationNASDAQ: LQDA

Common Stock · Q2 FY2026 · quarter ended Jun 2026

Common stock rises 4.7% from a year ago

Common stock stood at $89K at the end of Q2 FY2026, up 4.7% from a year earlier and up 1.1% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +4.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$89K+1.1% QoQ
Last fiscal yearDec 2025
$87K+2.4% YoY
Year agoJun 2025
$85K+4.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.7%——
1 year+2.4%——
3-year CAGR+10.8%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
87K USD
Year-over-year change
+2.4%
4-year CAGR
+13.7%

Common Stock vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +4.7% is the highest of 3, against a peer median of +1.7%.
  • Common stock amounts to 0.0% of total assets for LQDA, versus a peer median of 0.1%.
LQDA Competitors
Common Stock for LQDA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VCREVicore Pharma Holding ABJun 2026SEK 88.04M SEK——91.8%
INSMInsmed IncorporatedJun 2026$2.18M USD+3.4%+16.5%0.1%
UTHRUnited Therapeutics CorporationJun 2026$800K USD+0.0%+4.6%0.0%
LQDALiquidia CorporationJun 2026$89K USD+4.7%+10.8%0.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —+1.7%+10.5%0.1%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents57.49M93.28M83.68M176.48M190.68M
Short-term Investments00000
Net Receivables2.99M5.02M4.06M2.72M54.09M
Inventory000241K0
Other Current Assets(381)1.51M2.16M5.67M(54.09M)
Total Current Assets61.28M99.81M89.9M185.11M190.68M
Property, Plant & Equipment (Net)7.43M6.25M6.18M12.49M0
Goodwill3.9M3.9M3.9M3.9M3.9M
Intangible Assets4.39M3.73M3.43M3.16M2.95M
Long-term Investments00003.5M
Tax Assets00000
Other Non-current Assets16.73M15.51M14.92M25.66M126.9M
Total Non-current Assets32.45M29.39M28.43M45.21M137.25M
Total Assets93.73M129.2M118.33M230.31M327.93M
Account Payables1.07M2.2M1.4M4.69M3.68M
Short-term Debt002.62M18.02M58.41M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.16M2.86M8.54M18.66M20.32M
Total Current Liabilities7.33M8.8M18.55M41.78M135.77M
Long-term Debt10.41M19.88M43.42M97.37M132.94M
Deferred Tax Liabilities00003.64M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.14M6.59M6.71M7.3M4.75M
Total Non-current Liabilities21.14M29.98M52.49M111.26M147.42M
Total Liabilities28.46M38.78M71.04M153.04M283.19M
Common Stock52K64K69K85K87K
Retained Earnings(309.58M)(350.6M)(429.1M)(559.49M)(626.31M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity65.27M90.42M47.29M77.28M44.75M
Total Debt16.08M24.46M49.54M122.39M197.93M
Net Debt(41.41M)(68.82M)(34.14M)(54.09M)7.25M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.